Analytical Data
-
Gene name
DARC
- Application
-
Alternative Names
CD234; CCBP1; Dfy; FY; GPD; Duffy Antigen; Ackr1
-
Species
Mouse
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q53ZP8
-
Expression Region
Met71~Leu330
-
Molecular Weight
58kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DARC (Duffy Antigen Receptor for Chemokines), a membrane protein expressed on red blood cells and various other cell types, has garnered significant attention in biomedical research due to its multifaceted role in immune response and disease processes. Initially identified as the receptor for the Duffy blood group antigens, DARC plays a crucial role in the binding and transport of chemokines, which are pivotal signaling molecules involved in inflammation and immune cell trafficking. Studies have revealed its involvement in various diseases, including malaria, where the absence of DARC in certain populations provides resistance to Plasmodium vivax infection. This unique characteristic has spurred investigations into the potential therapeutic applications of DARC, particularly in modulating immune responses for various conditions, including autoimmune disorders and cancer. Moreover, the structural and functional analysis of DARC as a recombinant protein facilitates the understanding of its interactions with chemokines and other cellular receptors, paving the way for novel drug designs and therapeutic interventions. Research into DARC is further complicated by existing genetic variations among different human populations, adding a layer of complexity to its role in health and disease. Consequently, the study of DARC recombinant proteins not only aids in elucidating its biological functions but also contributes to the broader understanding of human immunology and disease resistance mechanisms.
